SynAct Pharma AB (8F8) Stock Price & Analysis
8F8 Stock Chart & Stats
- Day’s Range
- EUR 1.45 - EUR 1.49
- 52-Week Range
- EUR 0.97 - EUR 2.24
- Previous Close
- EUR 1.53
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 82.81M
- Enterprise Value
- EUR 1.17B
- Total Cash (Recent Filing)
- EUR 14.23M
- Total Debt (Recent Filing)
- EUR 929.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.46
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Extremely low leverage gives SynAct a relatively resilient capital structure for a clinical-stage company. Limited debt reduces interest and refinancing pressure, preserving more flexibility to direct available resources toward clinical development and future strategic financing.
Focused Drug Development
The focused pipeline and differentiated therapeutic approach provide a clear development strategy centered on resomelagon. If clinical evidence supports its intended immune-modulating profile, the candidate could offer meaningful partnering or commercialization potential in inflammatory diseases.
Losses Improved Versus 2023
The reduction in losses from 2023 indicates that reported financial performance has shown some capacity for improvement over the longer period. Although results remain negative, better loss control could extend funding runway and reduce the pace of capital consumption if sustained.
Bears Say
No Commercial Revenue
Without commercial revenue, SynAct has no established operating income stream to fund research, trials, or corporate costs. Its financial outlook therefore remains dependent on clinical progress and eventual monetization of resomelagon rather than on a diversified base of recurring sales.
Sustained Cash Burn
Persistent operating and free-cash-flow deficits show that the current business consumes substantial capital before generating commercial returns. Continued burn can constrain development flexibility and increase reliance on financing while SynAct advances its clinical pipeline.
Funding And Dilution Risk
Because losses and cash consumption remain substantial despite low debt, SynAct may need additional external capital to maintain development activities. Future equity financing could dilute existing shareholders, while unsuccessful fundraising could force slower clinical progress or reduced investment.
SynAct Pharma AB News
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
SynAct Pharma AB ( ($SE:SYNACT) ) just unveiled an update. SynAct Pharma has released further analysis from its Phase 2b ADVANCE study of resomelagon in treatment-naïve rheumatoid arthritis patients, reinforcing
SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
SynAct Pharma AB ( ($SE:SYNACT) ) has issued an announcement. SynAct Pharma has signed a term sheet with Brazilian drug maker Hipolabor Farmacêutica for a co-development and commercialization partnership around
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
What is SynAct Pharma AB’s market cap?
When is SynAct Pharma AB’s upcoming earnings report date?
How were SynAct Pharma AB’s earnings last quarter?
Is SynAct Pharma AB overvalued?
Does SynAct Pharma AB pay dividends?
What is SynAct Pharma AB’s EPS estimate?
How many shares outstanding does SynAct Pharma AB have?
What happened to SynAct Pharma AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of SynAct Pharma AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeppe Ovli Ovlesen
- Employees
- 8
- Website
- www.synactpharma.com
- Address
- Scheelevägen 2, Lund, SN, 223 63, SE
SynAct Pharma AB (8F8) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |